fashion -WSS

fashion

author：fashion 2025-08-12 08:25:18 - browse：578

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Medicare drug price negotiation legal challenge met with skepticism

WSS

Radiation, mainstay of cancer treatment, begins a fade

Winners, losers from Medicare’s list of drugs subject to price talks

What AAP's gender

Merck, Johnson & Johnson CEOs will testify on high drug prices

Medicare Advantage insurers face 0.2% cut to 2025 payments

How to make Best Hospitals ratings actually useful for patients

knowledge

fashion

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

Departing Stanford president retracts two papers

Drug repurposing or repositioning? The language matters

CDC advisory panel says seniors 'may' get RSV vaccine

State Dept. review finds Biden bears some blame for Afghanistan failures

Philips to halt sales of sleep apnea machines in U.S.

Drug repurposing or repositioning? The language matters

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Jerome Adams on the need for new antivirals for Covid

Psilocybin's anti

focus

What AAP's gender

AstraZeneca bets AAV gene therapy will still deliver the goods

How Long Island became the ‘eugenics capital of the world’

Medicare drug price negotiation legal challenge met with skepticism

How Long Island became the ‘eugenics capital of the world’

Vertex non

hotspot

knowledge

knowledge

knowledge